Guardant Health, Inc.

NasdaqGS:GH Rapport sur les actions

Capitalisation boursière : US$4.4b

Guardant Health Gestion

Gestion contrôle des critères 4/4

Le PDG Guardant Health est Helmy Eltoukhy, nommé en Jan2013, a un mandat de 11.83 ans. La rémunération annuelle totale est $ 11.59K, composée du salaire de 0.01% et des bonus 100%, y compris les actions et options de la société. détient directement 2.13% des actions de la société, d'une valeur de $ 93.22M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 3.2 ans.

Informations clés

Helmy Eltoukhy

Directeur général

US$11.6k

Rémunération totale

Pourcentage du salaire du PDG0.009%
Durée du mandat du directeur général11.8yrs
Propriété du PDG2.1%
Durée moyenne d'occupation des postes de direction3.5yrs
Durée moyenne du mandat des membres du conseil d'administration3.2yrs

Mises à jour récentes de la gestion

Recent updates

Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

Nov 08
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher

An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Oct 25
An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 24
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen

Aug 21

Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Jul 31
Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce

Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jul 12
Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate

Guardant: Double-Digit Sales Projections Come At A Cost

Jun 06

Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Jun 04
Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?

Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

May 14
Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Mar 29
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Analyse de la rémunération des PDG

Comment la rémunération de Helmy Eltoukhy a-t-elle évolué par rapport aux bénéfices de Guardant Health?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$512m

Jun 30 2024n/an/a

-US$491m

Mar 31 2024n/an/a

-US$461m

Dec 31 2023US$12kUS$1

-US$479m

Sep 30 2023n/an/a

-US$432m

Jun 30 2023n/an/a

-US$508m

Mar 31 2023n/an/a

-US$665m

Dec 31 2022US$12kUS$1

-US$655m

Sep 30 2022n/an/a

-US$606m

Jun 30 2022n/an/a

-US$551m

Mar 31 2022n/an/a

-US$419m

Dec 31 2021US$14kUS$1

-US$406m

Sep 30 2021n/an/a

-US$409m

Jun 30 2021n/an/a

-US$379m

Mar 31 2021n/an/a

-US$336m

Dec 31 2020US$114mUS$210k

-US$254m

Sep 30 2020n/an/a

-US$185m

Jun 30 2020n/an/a

-US$120m

Mar 31 2020n/an/a

-US$77m

Dec 31 2019US$915kUS$500k

-US$76m

Sep 30 2019n/an/a

-US$76m

Jun 30 2019n/an/a

-US$87m

Mar 31 2019n/an/a

-US$97m

Dec 31 2018US$818kUS$480k

-US$85m

Sep 30 2018n/an/a

-US$75m

Jun 30 2018n/an/a

-US$84m

Mar 31 2018n/an/a

-US$83m

Dec 31 2017US$4mUS$460k

-US$89m

Rémunération vs marché: La rémunération totale de Helmy ($USD 11.59K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.50M ).

Rémunération et revenus: La rémunération de Helmy a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Helmy Eltoukhy (45 yo)

11.8yrs

Titularisation

US$11,591

Compensation

Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Helmy Eltoukhy
Co-Founder11.8yrsUS$11.59k2.13%
$ 93.2m
AmirAli Talasaz
Co-CEO & Director3.3yrsUS$26.42k2.2%
$ 96.4m
Michael Bell
Chief Financial Officer3.8yrsUS$4.12m0.019%
$ 852.5k
Darya Chudova
Chief Technology Officerno dataUS$4.76m0.044%
$ 1.9m
Craig Eagle
Chief Medical Officer3.5yrsUS$3.49m0.019%
$ 823.6k
Christopher Freeman
Chief Commercial Officer3.4yrsUS$3.52m0.025%
$ 1.1m
Kumud Kalia
Chief Information Officer4.8yrspas de données0.014%
$ 628.1k
Zarak Khurshid
Vice President of Investor Relationsno datapas de donnéespas de données
John Saia
Chief Legal Officer & Corporate Secretary4.5yrsUS$6.02m0.027%
$ 1.2m
Jennifer Higgins
Senior Vice President of Public Affairsno datapas de donnéespas de données
Stephen Murphy
Senior Vice President of Marketingless than a yearpas de donnéespas de données
Terilyn Monroe
Chief People Officerless than a yearpas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

51yo

Âge moyen

Gestion expérimentée: L'équipe de direction de GH est considérée comme expérimentée (ancienneté moyenne 3.5 ans).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Helmy Eltoukhy
Co-Founder11.8yrsUS$11.59k2.13%
$ 93.2m
AmirAli Talasaz
Co-CEO & Director11.8yrsUS$26.42k2.2%
$ 96.4m
Myrtle Potter
Independent Director3.1yrsUS$425.21k0.011%
$ 483.3k
Ian T. Clark
Lead Independent Director7.8yrsUS$470.21k0.0068%
$ 298.7k
Roberto Mignone
Directorless than a yearpas de donnéespas de données
Steve Krognes
Independent Director2.4yrsUS$425.21k0.0080%
$ 350.8k
Musa Tariq
Independent Director1.7yrsUS$725.30k0.0040%
$ 176.7k
Vijaya Gadde
Independent Director4.4yrsUS$425.21k0.014%
$ 624.6k
Meghan Joyce
Independent Director3.3yrsUS$425.21k0.0062%
$ 270.7k
Manuel Medina
Directorless than a yearpas de donnéespas de données

3.2yrs

Durée moyenne de l'emploi

50.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de GH sont considérés comme expérimentés (ancienneté moyenne 3.2 ans).